Your search for major depressive disorder returned 59 results

Researchers conducted a phase 2 trial to assess the safety and efficacy of single-dose psilocybin treatment for major depressive disorder.

Researchers analyzed MRI-derived images of participants with mental illness to evaluate the heterogeneity of gray matter volume deviations.

Researchers investigated the all-cause risk for mortality in patients with major depressive disorder exhibiting suicidal behavior.

In a systematic review and meta-analysis, estimates for depressive disorders in children younger than 13 years old were evaluated.

Researchers evaluated the magnitude, timing, and durability of antidepressant effects and safety of a single dose of psilocybin in patients with major depressive disorder.

Researchers sought to evaluate the safety of COVID-19 vaccination in pregnant and breastfeeding women with autoimmune diseases.

An eye-tracking test has identified a potential performance-based biomarker for the early diagnosis of autism spectrum disorder (ASD).

Researchers examined the patient burden of tardive dyskinesia.

Researchers sought to assess the cognitive effects of PTSD in patients with drug-resistant epilepsy who have PTSD symptoms.

A study sought to determine the prevalence of depression and cognitive dysfunction in patients receiving TAVR for aortic stenosis and its effect on mortality.

Researchers evaluated the risk for major depressive disorder among patients with HIV infection.

Botulinum toxin injections can improve quality of life for patients across a variety of aspects of health care, including pain management, urology, dermatology, and more.

A study was conducted to determine the effect of mental health disorders on postoperative outcomes following EVAR in patients who are veterans.

In a retrospective cohort study, researchers assessed the association between prurigo nodularis with sleep disorders.

Ulotaront is a trace amine-associated receptor 1 agonist with 5-HT1A agonist activity.

Researchers sought to assess the association between sleep-related adverse events and antidepressant dosage.

Researchers sought to assess how objective cognitive deficits in depression are associated with symptoms, neural circuits, and treatment outcomes.

In a multicenter, observational, cohort study, researchers investigated the incidence dynamics and long-term neurologic outcome of neuro-COVID disorders.

Researchers sought to assess the effectiveness and tolerability of vortioxetine in improving depressive symptoms, cognitive performance, functioning, and health-related quality of life in patients with depression and early dementia.

Some men have said that honest communication and community-based approaches make them more like to engage in mental health care.

The US Preventive Services Task Force (USPSTF) recommends depression screening for all adults and anxiety screening for younger adults.

Researchers examined long-term associations between COVID-19 infection and the risk of mortality and multiorgan complications among older adults.

Researchers aimed to assess the association between metformin and dementia risk and compare this with patients with type 2 diabetes who do not use antidiabetic drugs.

Psilocybin treatment in a community setting appears safe and effective for patients with cancer and depression.

Researchers assessed whether clinical severity and instability, during a 2-month period, were predictors of later risk for psychiatric hospitalization within the next 6 months.

Patients with MDD were randomly assigned in a 1:1:1 ratio to receive 1.5 mg daily cariprazine, 3.0 mg daily cariprazine, or placebo for 6 weeks.

The FDA has approved Rexulti (brexpiprazole) for the treatment of agitation associated with dementia due to Alzheimer disease.

A study was conducted to determine the effects of switching or augmenting antidepressant therapy in adults with treatment-resistant depression.

Investigators assessed the prevalence of exposure to medications with potential drug-drug interactions to ritonavir-containing COVID-19 therapy among US adults.

Anxiety, depressive, and panic disorders are all common psychiatric comorbidities found in patients with migraine and headache disorders.